greenovation Biotech GmbH

Greenovation develops plant-made next-generation therapeutics using its proprietary BryoTechnology platform. The company aims to optimize the production of highly-efficient glycoproteins for the treatment of rare diseases.

Moss-aGal is Greenovation's lead product which exhibits optimized glycosylation patterns and superior features with respect to pharmacokinetics, pharmacodynamics and biodistribution in preclinical studies.

This proprietary moss-expressed protein is intended for treatment of patients with Fabry Disease, a rare genetic lysosomal storage disorder that is caused by deficient activity – subnormal or absent – of the lysosomal enzyme α-galactosidase A.

Greenovation is a privately owned biopharmaceutical company based in Heilbronn, Germany. It was founded in 1999 by Prof. Dr. Ralf Reski and Prof. Dr. Gunter Neuhaus. Today, Greenovation Biotech GmbH is majority-owned by Zukunftsfonds Heilbronn and L-EigenkapitalAgentur (Karlsruhe).